The global market, in terms of value, is projected to grow at a CAGR of 5.9% from 2019 to 2026, and market to reach USD 1.8 billion by 2026. The report provides analysis of global Ovarian Cancer Diagnostics market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
One of the most prevalent kinds of cancer in females is ovarian cancer. It is a cancer which begins in the ovaries. Ovary is a woman reproductive organ that contains eggs or ova. There are two ovaries in the woman reproductive scheme: one on either side of the uterus. Hormones include progesterone and estrogen are produced by ovaries. Eggs are also produced by ovaries. Ovarian cancer can only be detected when it reaches the abdomen and pelvis. The ovarian cancer is more deadly and difficult to cure at this point. In the initial stage, it can be treated more effectively if it is limited to the ovarian cells.
Request Free Sample Report Pages for Better Understanding, Download Here
Market growth can be ascribed to increased ovarian cancer incidence and the development of new diagnostic products. As of 2018, all gynecological diseases had the largest death level. It caused almost 14,000 fatalities in the United States in 2018. No particular signs make it progressively hard to diagnose the illness soon. The precise cause variables stay unclear, generating a main lack of studies to clarify the fundamental molecular processes.
Women 60 years of age and older are more predisposed to it. As it is often diagnosed in sophisticated phases, there are restricted therapy choices. In addition, the mortality levels among Caucasian females were greater on a racial grounds than among African-American females. For the stadium of ovarian disease, the International Federation of Gynecology and Obstetrics (FIGO) is used. The staging method helps locate, calculate the size of ovarian tumors and detect invasion and metastasis.
Early detection and diagnosis enhance patient survival rates considerably. For example, patients with ovarian phase 1 disease in epithelial cells have a survival level of almost 90%, while patients with phase 4–the most sophisticated phase–have a mere 15% survival level. The technological progress in PET and MRI and in the treatment of BRCA diseases has had a positive influence on the development of the industry.
The diagnostic landscape is progressively moving towards genetic testing and advice. Since the disease has a strong danger of gene mutation heritage, recommendations on ovarian cancer diagnosis suggest genetic therapy and screening for all physicians. BRCA1/2 was earlier the most prominent experiment; however, progress in medicine has now enabled more than 20 genes to be tested in every person.
Due to the accessibility of sophisticated diagnostic technology, North America is anticipated to dominate the international industry for ovarian cancer diagnostics. People’s awareness of the disease is also one of the main variables that boost the industry in this region. The ovarian cancer industry in Asia-Pacific is expected to grow rapidly as ovarian cancer incidence increases. A lack of knowledge about the condition and availability of sophisticated diagnostic procedures and therapy is probable to propel Middle East & Africa’s ovarian diagnostic industry in underdeveloped nations such as Lebanon, Syria, Cyprus, Turkey and Iraq.
The incidence of ovarian cancer has declined globally in recent centuries.
Although ultrasound imaging is the diagnosis fist line, the technique cannot be used for disease staging.
In 2018 HER2 and BRCA1/2 exams, computerized Tomography (CT) testing is preferably used in screening CA125.
Based on the growing knowledge of early diagnosis and genetic testing, the experiment is anticipated to show fast development in the forecast period.
The ovarian cancer industry is anticipated to increase at a large pace in Asia Pacific during the forecast period.
Key Players & Strategies
Some of the main competitors are GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd.; AstraZeneca plc; Johnson & Johnson Services, Inc.; Siemens Healthcare GmbH; Bio-Rad Technologies Inc.; Thermo Fisher Scientific; and Abbott. Major competitors are increasingly concentrating on strategic activities such as launch & growth of products, combinations and purchases, licensing agreements and co-development agreements, making this industry extremely competitive. Foundation Medicine, for example, announced in June 2019 that it has obtained a FDA-approved extensive screening for genomic profiling for first-line maintenance treatment for BRCA-mutated metastatic ovarian cancer. This experiment can identify mutations of BRCA1/2 including germline and somatic mutations.
Market, by Diagnosis Type
- CT Scan
- PET Scan
- MRI Scan
- Blood Test
- ER & PR
- KRAS Mutation
Market, by Cancer Type
- Germ Cell Tumor
- Stromal Cell Tumor
- Epithelial Tumor
Market, by End-use
- Cancer Diagnostic Centers
- Hospital Laboratories
- Research Institutes
Market, by Geography
- North America.
- Latin America
- Middle East and Africa (MEA)
The market research study on “Ovarian Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type, Diagnostics Type, End Use, By Region – Global Industry Size, Share, Trends and Forecast 2019 – 2026” offers detailed insights on global Ovarian Cancer Diagnostics market segments with market dynamics and their impact. The report also covers basic technology development policies.
This study offers an assessment of the recent sector trends in each subsection from 2015 to 2026 and forecasts income development at the worldwide, regional, and nation levels. ARC has divided the Ovarian Cancer Diagnostics market into the drug and region for the purpose of this research:
Would like to place an order or any question, please feel free to contact at email@example.com | +1 407 915 4157
The report is readily available and can be dispatched immediately after payment confirmation.
Buy this premium research report – https://www.acumenresearchandconsulting.com/buy-now/0/1550
About Acumen Research and Consulting:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.